Search
forLearn
5 / 801 resultslearn PTT-6®
learn Beta glucan
learn heptyl glucoside
learn Biotinyl-GHK
Research
5 / 153 results
research A case of neurosyphilis with inflammation of the oral mucosa
The woman was cured of neurosyphilis after treatment with penicillin.
research Screening for latent infectious disease in patients with alopecia areata before initiating JAK inhibitors therapy: a single-center real-world retrospective study
Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.
research Unusual Diffuse Hair Loss
The man's hair loss was due to syphilis, and his hair regrew after treatment.
research Syphilis: A great imitator
Syphilis has a wide range of symptoms that can look like other diseases, and if not treated, it can progress to a more serious stage, especially in HIV-positive patients.
research Syphilis: today
Syphilis is becoming more common and remains a major health problem due to challenges in prevention and treatment.
Community Join
5 / 1000+ resultscommunity 18m, already balding. Is a hair system the way to go? I don’t have the strength to go bald this young
An 18-year-old with early hair loss is advised to consider minoxidil and finasteride, with a doctor's consultation recommended. Alternatives like a hair system or shaving are suggested due to potential medication side effects and lifelong commitment.
community Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community Phase II for Technoderma Therepeutic's TDM-105795 set to begin in April tentatively
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.